Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constance Delaby

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Annales De Biologie Clinique|January 9, 2026
Clinical biology and artificial intelligence: Objectives of the SFBC WorkgroupWalid Sabeur, Pierre-Adrien Bihl, Bruno Gauthier, et al.
Plos One|February 20, 2014
Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorderSylvain Lehmann, Aroa Relano-Gines, Sarah Resina, et al.
Neuromuscular Disorders : NMD|October 31, 2020
The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathiesAurélien Perrin, Raul Juntas Morales, François Rivier, et al.
The Lancet. Neurology|September 3, 2018
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional studyJuan Fortea, María Carmona-Iragui, Bessy Benejam, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 26, 2013
Impact of harmonization of collection tubes on Alzheimer's disease diagnosisSylvain Lehmann, Susanna Schraen, Isabelle Quadrio, et al.
Alzheimer'S Research & Therapy|February 2, 2022
The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 aloneConstance Delaby, Teresa Estellés, Nuole Zhu, et al.
Alzheimer'S Research & Therapy|December 6, 2014
A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profilesSylvain Lehmann, Julien Dumurgier, Susanna Schraen, et al.
Current Alzheimer Research|January 11, 2018
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF BiomarkersOlivier Vercruysse, Claire Paquet, Audrey Gabelle, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementiasDaniel Alcolea, Constance Delaby, Laia Muñoz, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2019
The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disordersDaniel Alcolea, Jordi Clarimón, María Carmona-Iragui, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Annales De Biologie Clinique|January 9, 2026
Clinical biology and artificial intelligence: Objectives of the SFBC WorkgroupWalid Sabeur, Pierre-Adrien Bihl, Bruno Gauthier, et al.
Plos One|February 20, 2014
Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorderSylvain Lehmann, Aroa Relano-Gines, Sarah Resina, et al.
Neuromuscular Disorders : NMD|October 31, 2020
The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathiesAurélien Perrin, Raul Juntas Morales, François Rivier, et al.
The Lancet. Neurology|September 3, 2018
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional studyJuan Fortea, María Carmona-Iragui, Bessy Benejam, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 26, 2013
Impact of harmonization of collection tubes on Alzheimer's disease diagnosisSylvain Lehmann, Susanna Schraen, Isabelle Quadrio, et al.
Alzheimer'S Research & Therapy|February 2, 2022
The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 aloneConstance Delaby, Teresa Estellés, Nuole Zhu, et al.
Alzheimer'S Research & Therapy|December 6, 2014
A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profilesSylvain Lehmann, Julien Dumurgier, Susanna Schraen, et al.
Current Alzheimer Research|January 11, 2018
Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF BiomarkersOlivier Vercruysse, Claire Paquet, Audrey Gabelle, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementiasDaniel Alcolea, Constance Delaby, Laia Muñoz, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2019
The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disordersDaniel Alcolea, Jordi Clarimón, María Carmona-Iragui, et al.
Pageof 8